EXPERT OPINION ON PHARMACOTHERAPY, published by Taylor & Francis Ltd, stands as a vital resource in the fields of medicine and pharmacology, consistently recognized for its significant contributions to both disciplines. With an impressive impact factor, this journal ranks in the second quartile (Q2) across several key categories, including Medicine (miscellaneous), Pharmacology, and Medical Pharmacology, underscoring its influence within the academic community. Since its inception in 1999, the journal has provided a platform for peer-reviewed articles that critically evaluate emerging therapies and innovative pharmacological approaches, making it essential reading for researchers, healthcare professionals, and students alike. Although it operates under a subscription model, its comprehensive coverage of pharmacotherapeutic developments ensures that it remains a cornerstone for those seeking new insights and expert analyses in the rapidly evolving landscape of drug therapy.

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Expert Review of Neurotherapeutics is an esteemed journal published by Taylor & Francis Ltd, focusing on the rapidly evolving field of neurotherapeutics. With an ISSN of 1473-7175 and an E-ISSN of 1744-8360, this publication aims to bridge the gap between clinical and preclinical research, providing a platform for innovative therapeutic strategies in neurology and neuroscience. The journal boasts impressive impact factor rankings, categorized as Q2 in both clinical neurology and miscellaneous neuroscience, and Q1 in medical pharmacology for 2023. Its reputable placement in Scopus rankings, including Rank #82/400 in clinical neurology, underscores its significance within the medical research community. Spanning from 2001 to 2024, the journal publishes critical reviews and original research articles aimed at enhancing understanding and treatment in neurological disorders. Although it currently does not offer open access, articles published in the journal are crucial for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in neurotherapeutics. With its strong emphasis on rigorous peer-reviewed content, Expert Review of Neurotherapeutics continues to be a vital resource for those dedicated to improving patient outcomes in the realm of neurology.

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

MOLECULAR BIOTECHNOLOGY, published by SPRINGERNATURE, is a pivotal journal in the fields of applied microbiology, molecular biology, biochemistry, and biotechnology. Since its inception in 1994, the journal has aimed to disseminate high-quality research that explores the intersection of molecular biology and technology, fostering advancements in biotechnology applications. With an ISSN of 1073-6085 and an E-ISSN of 1559-0305, it has established itself as a significant contributor to the scientific community, currently holding a Q3 ranking across multiple categories including Applied Microbiology & Biotechnology and Biochemistry in the 2023 metrics. Although not an open access publication, the journal remains accessible through various institutional subscriptions, providing valuable insights and findings to researchers and professionals. Given its ongoing commitment to quality and relevance, MOLECULAR BIOTECHNOLOGY serves as an essential resource for those involved in cutting-edge research and innovation in molecular biotechnology and related disciplines.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, published by BIOLIFE SAS, is a pivotal platform in the fields of Cancer Research, Endocrinology, Immunology, and Physiology, addressing fundamental aspects of biological regulation and homeostasis. Since its inception in 1987, this journal has consistently contributed to the advancement of knowledge, showcasing innovative research and breakthroughs that are instrumental for professionals, researchers, and students alike. Although categorized in the Q4 quartile across multiple disciplines, the journal offers a unique perspective that encourages exploration into underrepresented areas, underscoring its role in fostering scientific dialogue and collaboration. With ISSN 0393-974X and E-ISSN 1724-6083, the journal remains a crucial resource for those invested in understanding the complexities of homeostatic agents and their implications in health and disease. Based in Silva Marina, Italy, it invites contributions that broaden the horizons of contemporary biomedical research.

Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.